Education & Training
A practical guide to price, cost and value in medicines
When people say a medicine is expensive, they may mean its list price, what they personally paid, what their insurer spent, or that its cost seems out of proportion to its benefit. These are different claims. This guide sets out the main distinctions, walks through a hypothetical example, and offers questions for reading any pricing or value claim more carefully.
01
Four numbers that get confused
List price is the manufacturer's published price before discounts; it often anchors patient coinsurance and deductibles. Net price is what the manufacturer receives after rebates and other concessions, usually confidential. Patient out-of-pocket cost depends on plan design: a flat copay, a percentage of a reference price, or the full amount during a deductible phase. Total cost of care is wider still, including administration, monitoring and downstream effects such as avoided or added hospital use. A headline about a drug's price usually refers to just one of these, and the others can tell a very different story.
02
An illustrative scenario
Imagine a hypothetical new treatment for a chronic condition, priced well above an older generic option. A health technology assessment body reviews it. Trial data suggest it helps some patients more than the older option, with uncertainty about long-term effects. The assessors model expected benefit over many years, convert it into quality-adjusted life years, and compare the extra cost per extra QALY with the threshold their system uses. They might conclude it is cost-effective only for a subgroup, or only at a lower price, which often prompts confidential negotiation. Meanwhile an insured patient may still face a high charge if their coinsurance is calculated on list price. The assessment, the negotiated price and the patient's bill are three separate outcomes of the same product.
03
Questions worth asking of any value claim
Compared with what: the alternative chosen as comparator shapes every result. Over what time horizon, and how were benefits beyond the trial period estimated? Whose costs are counted: the payer's, the health system's, or society's including caregiving and lost work? Which price was used, list or estimated net? How sensitive is the conclusion to plausible changes in assumptions? Who funded the analysis, and were the model and inputs published? These questions do not settle whether a medicine is worth its price, but they show how much a conclusion depends on choices made by the analyst.
04
Limits of value frameworks
Cost-effectiveness measures are tools for allocating shared budgets, not judgments about any individual's care. QALYs have been criticized for how they treat disability, chronic illness and rare diseases, and approaches to using them differ between health systems. Thresholds reflect policy choices rather than natural constants. Net prices are often hidden, so outside analyses rely on estimates. And a favorable or unfavorable assessment says nothing about whether a particular person should start or stop a medicine; that is a clinical decision for patients and their clinicians. This guide is general education and does not evaluate any specific product.